Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Pa...(CV)infections. The pulmonology portfolio...)

Date:3/18/2008

CV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks re
'/>"/>

SOURCE InterMune, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
2. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
9. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
10. Smithfield Foods, Inc. Statement Regarding Animal Cloning
11. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply